Published in Circulation on March 31, 1998
Simvastatin in Secondary Progressive Multiple Sclerosis (MS-OPT) | NCT03896217
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol (2007) 3.96
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med (2002) 3.17
Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 2.70
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol (2006) 2.61
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation (2003) 2.30
Nitric oxide and oxidative stress in vascular disease. Pflugers Arch (2010) 2.29
Rho GTPases, statins, and nitric oxide. Circ Res (2005) 2.21
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke (2005) 2.13
Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation (2011) 1.91
Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol (2007) 1.89
Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest (2000) 1.76
Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma (2009) 1.67
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart (2005) 1.65
Involvement of heat shock factor 1 in statin-induced transcriptional upregulation of endothelial thrombomodulin. Circ Res (2008) 1.64
Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res (2003) 1.59
Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol (2005) 1.55
Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial. Heart (2009) 1.54
Are statins diabetogenic? Curr Opin Cardiol (2011) 1.54
Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med (2004) 1.50
Rosuvastatin attenuates the elevation in blood pressure induced by overexpression of human C-reactive protein. Hypertens Res (2011) 1.50
Atherosclerosis, cholesterol, nutrition, and statins--a critical review. Ger Med Sci (2007) 1.49
Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells. Circulation (2005) 1.45
Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets (2005) 1.42
Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy. World J Surg (2014) 1.38
Statins and micronutrients: unanswered questions. J R Soc Med (2004) 1.38
Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation (2011) 1.31
Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res (2012) 1.31
Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol (2003) 1.30
Tenascin-C modulates matrix contraction via focal adhesion kinase- and Rho-mediated signaling pathways. Mol Biol Cell (2002) 1.27
ROCKs as therapeutic targets in cardiovascular diseases. Expert Rev Cardiovasc Ther (2005) 1.25
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis (2007) 1.24
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today (2010) 1.24
Peroxynitrite mediates diabetes-induced endothelial dysfunction: possible role of Rho kinase activation. Exp Diabetes Res (2010) 1.23
Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis (2008) 1.19
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis (2010) 1.17
Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol (2011) 1.17
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size. Circ Res (2005) 1.14
Functional expression of endothelial nitric oxide synthase fused to green fluorescent protein in transgenic mice. Am J Pathol (2003) 1.13
A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol (2001) 1.13
Cardioprotective PKG-independent NO signaling at reperfusion. Am J Physiol Heart Circ Physiol (2010) 1.12
HuR regulates the expression of stress-sensitive genes and mediates inflammatory response in human umbilical vein endothelial cells. Proc Natl Acad Sci U S A (2010) 1.11
Differences in citation frequency of clinical and basic science papers in cardiovascular research. Med Biol Eng Comput (2011) 1.10
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
Bypassing vasopressin receptor signaling pathways in nephrogenic diabetes insipidus. Semin Nephrol (2008) 1.07
Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol (2011) 1.07
Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J (2001) 1.05
Retracted Sphingosine-1-phosphate receptor-2 deficiency leads to inhibition of macrophage proinflammatory activities and atherosclerosis in apoE-deficient mice. J Clin Invest (2010) 1.05
Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 1.05
Differential modulation of nitric oxide synthases in aging: therapeutic opportunities. Front Physiol (2012) 1.04
Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des (2009) 1.04
Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. EMBO Mol Med (2014) 1.04
Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg (2004) 1.03
Recent achievements in the management of Raynaud's phenomenon. Vasc Health Risk Manag (2010) 1.02
A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol (2011) 1.02
Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol (2004) 1.01
Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signal (2011) 1.00
Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab (2008) 1.00
Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism. Int J Radiat Oncol Biol Phys (2007) 0.99
Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br J Pharmacol (2000) 0.99
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.98
Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging (Albany NY) (2010) 0.98
A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med (2003) 0.97
Simvastatin attenuates contrast-induced nephropathy through modulation of oxidative stress, proinflammatory myeloperoxidase, and nitric oxide. Oxid Med Cell Longev (2012) 0.96
Reduction of radiation-induced vascular nitrosative stress by the vitamin E analog γ-tocotrienol: evidence of a role for tetrahydrobiopterin. Int J Radiat Oncol Biol Phys (2010) 0.96
Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis. Antioxid Redox Signal (2013) 0.96
Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovasc Res (2012) 0.96
Pentoxifylline enhances the radioprotective properties of γ-tocotrienol: differential effects on the hematopoietic, gastrointestinal and vascular systems. Radiat Res (2010) 0.95
Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin. Haematologica (2010) 0.94
Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension (2013) 0.94
Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med (2005) 0.94
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart (2005) 0.93
Rising statin use and effect on ischemic stroke outcome. BMC Med (2004) 0.93
Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis (2008) 0.93
BMPER is upregulated by statins and modulates endothelial inflammation by intercellular adhesion molecule-1. Arterioscler Thromb Vasc Biol (2009) 0.92
Sexual dimorphism in reduced-size liver ischemia and reperfusion injury in mice: role of endothelial cell nitric oxide synthase. Proc Natl Acad Sci U S A (2003) 0.92
Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium (2006) 0.92
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome. Microcirculation (2009) 0.92
Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev (2003) 0.92
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart (2006) 0.92
Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med (2000) 0.92
The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation. Vasc Health Risk Manag (2007) 0.91
Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches. J Korean Med Sci (2015) 0.91
Modulation by simvastatin of iberiotoxin-sensitive, Ca2+-activated K+ channels of porcine coronary artery smooth muscle cells. Br J Pharmacol (2007) 0.91
Simvastatin improves learning and memory in control but not in olfactory bulbectomized rats. Psychopharmacology (Berl) (2011) 0.90
Bicuspid aortic valve disease: the role of oxidative stress in Lrp5 bone formation. Cardiovasc Pathol (2011) 0.90
Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag (2005) 0.89
Statins and anti-inflammatory therapies for subarachnoid hemorrhage. Curr Treat Options Neurol (2012) 0.89
Statins in traumatic brain injury. Neurotherapeutics (2010) 0.89
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res (2011) 0.89
Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clin Sci (Lond) (2011) 0.89
SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects. J Biomed Sci (2012) 0.88
Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis (2006) 0.88
Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science (1999) 7.13
Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest (1995) 5.09
Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature (2000) 4.92
Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem (1998) 3.97
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol (2001) 3.65
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A (1998) 3.23
Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res (1998) 2.39
Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew. Proc Natl Acad Sci U S A (1992) 2.37
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest (2001) 2.19
Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). Circulation (2000) 2.14
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem (1997) 2.12
Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem (1995) 2.11
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol (1999) 2.07
PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (1999) 2.02
Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem (2001) 1.97
VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci (1999) 1.89
Fatty acid modulation of endothelial activation. Am J Clin Nutr (2000) 1.81
Neuroprotection mediated by changes in the endothelial actin cytoskeleton. J Clin Invest (2000) 1.76
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem (1999) 1.76
Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk (2001) 1.65
Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol (2001) 1.64
Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol (2000) 1.49
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke (2001) 1.47
[New findings on the action of HMG-CoA-reductase inhibitors]. Dtsch Med Wochenschr (1997) 1.42
Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription. Circulation (2000) 1.41
Targeting Rho in cardiovascular disease. Circ Res (2000) 1.38
Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol (1998) 1.26
Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem (1997) 1.24
PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med (2007) 1.21
A functional role of I kappa B-epsilon in endothelial cell activation. J Immunol (2000) 1.19
Regulation of myogenic terminal differentiation by the hairy-related transcription factor CHF2. J Biol Chem (2001) 1.19
PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation (2001) 1.18
Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem (1999) 1.15
Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. J Cereb Blood Flow Metab (2000) 1.15
Evolution and organization of the human protein C gene. Proc Natl Acad Sci U S A (1986) 1.14
Simvastatin decreases IL-6 and IL-8 production in epithelial cells. J Dent Res (2006) 1.13
Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ Res (2000) 1.12
The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs. Nucleic Acids Res (1985) 1.09
Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia (2011) 1.07
Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem (1995) 1.06
Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol (2000) 1.03
Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol (1998) 1.00
Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med (2000) 0.96
Structural requirements for inhibition of cytokine-induced endothelial activation by unsaturated fatty acids. J Lipid Res (1998) 0.95
Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma. The role of constitutive NF-kappa B activity. J Biol Chem (1996) 0.94
ROCK1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression. Curr Mol Med (2013) 0.89
Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension. Clin Pharmacol Ther (2011) 0.88
Role of Rho kinase isoforms in murine allergic airway responses. Eur Respir J (2011) 0.87
Molecular biology of atherosclerosis. Int J Cardiol (1997) 0.87
Hydrogen peroxide-mediated transcriptional induction of macrophage colony-stimulating factor by TGF-beta1. J Immunol (1997) 0.85
[Regulation of endothelial NO production by Rho GTPase]. Med Klin (Munich) (1999) 0.83
Induction of endothelial-leukocyte interaction by interferon-gamma requires coactivation of nuclear factor-kappaB. Arterioscler Thromb Vasc Biol (2001) 0.83
Modulation of bradykinin receptor ligand binding affinity and its coupled G-proteins by nitric oxide. J Biol Chem (1997) 0.82
A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk (1999) 0.81
Salicylates and vascular smooth muscle cell proliferation: molecular mechanisms for cell cycle arrest. Trends Cardiovasc Med (2001) 0.78
Is smooth muscle growth in primate arteries regulated by endothelial nitric oxide synthase? J Vasc Surg (1998) 0.78
Effect of lipid-lowering therapy on vasomotion and endothelial function. Curr Cardiol Rep (1999) 0.77
Lipid management with statins. The lower the better? Z Kardiol (2004) 0.76
Statins for stroke: the second story? Circulation (2001) 0.76
Assessing induction of I kappa B by nitric oxide. Methods Enzymol (1999) 0.76
Activation of guanine nucleotide-binding proteins and induction of endothelial tissue-type plasminogen activator gene transcription by alcohol. J Biol Chem (1999) 0.75
On being a physician. Am J Med (1990) 0.75
Toxic action of nitric oxide on myocardial cells: direct evidence from gene transfer in vivo. J Card Fail (1996) 0.75
Nuclear run-on assay to study gene transcription in vascular cells. Methods Mol Med (1999) 0.75